• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Gerd R Burmester, Iain B McInnes, +15 authors Michael E. Weinblatt
  • Medicine
  • Annals of the rheumatic diseases
  • 2017 (First Publication: 16 February 2017)
  • Objectives Despite the therapeutic value of current rheumatoid arthritis (RA) treatments, agents with alternative modes of action are required. Mavrilimumab, a fully human monoclonal antibodyContinue Reading
  • Richard H de Boer, Yves Humblet, +6 authors Johan Vansteenkiste
  • Medicine
  • Annals of oncology : official journal of the…
  • 2008 (First Publication: 7 October 2008)
  • BACKGROUND Vandetanib (ZACTIMA; ZD6474) is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. The safety and tolerability ofContinue Reading
  • Mark P. Saunders, Richard Wilson, +4 authors Eric Van Cutsem
  • Medicine
  • Cancer Chemotherapy and Pharmacology
  • 2008 (First Publication: 29 January 2009)
  • PurposeThe safety and tolerability of vandetanib (ZACTIMA™; ZD6474) plus FOLFIRI was investigated in patients with advanced colorectal cancer (CRC).MethodsPatients eligible for first- or second-lineContinue Reading
  • Michael Michael, Peter Gibbs, Robert Nelson Smith, Alex Godwood, Stuart W. Oliver, Niall C. Tebbutt
  • Medicine
  • Investigational New Drugs
  • 2008 (First Publication: 1 June 2009)
  • SummaryBackground: Vandetanib (ZACTIMA™) is a once-daily oral inhibitor of vascular endothelial growth factor, epidermal growth factor and RET receptor tyrosine kinases. The safety and tolerabilityContinue Reading
  • G Burmester, Iain B McInnes, +10 authors Michael E. Weinblatt
  • Medicine
  • 2015 (First Publication: 1 June 2015)
  • Background Of patients with RA, ∼40% of do not achieve a minimal acceptable improvement (ACR20) despite modern biologic therapy.1,2,3 Granulocyte-macrophage colony-stimulating factor (GM–CSF) isContinue Reading
  • Iain B McInnes, G Burmester, +10 authors Michael E. Weinblatt
  • Medicine
  • 2015 (First Publication: 1 June 2015)
  • Background Macrophages are pivotal to the pathogenesis of rheumatoid arthritis (RA), and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophageContinue Reading
  • Joel M. Kremer, G Burmester, +5 authors David D. Close
  • Medicine
  • 2015 (First Publication: 1 June 2015)
  • Background Active RA significantly impairs patients9 health-related quality of life (HRQOL) and physical function. Granulocyte-macrophage colony-stimulating factor (GM–CSF) plays a key role inContinue Reading
  • Tsutomu Takeuchi, Yoshiya Tanaka, David Henry Close, Alex Godwood, Chi-Yuan Wu, Didier Saurigny
  • Medicine
  • Modern rheumatology
  • 2015 (First Publication: 2 January 2015)
  • Abstract Objective. A phase IIa study investigated efficacy and safety/tolerability of ascending doses of mavrilimumab (anti-granulocyte-macrophage colony-stimulating factor receptor [GM-CSFR]αContinue Reading